HC Wainwright Has Positive View of FocalTherics Q3 Earnings

FocalTherics (NASDAQ:FOCL) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for FocalTherics in a research report issued to clients and investors on Tuesday, August 25th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.17) for the quarter, up from their previous estimate of ($0.22). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for FocalTherics’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for FocalTherics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.47) EPS, FY2028 earnings at ($0.04) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.25 EPS.

Other analysts also recently issued research reports about the stock. Piper Sandler reissued a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Finally, Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.75.

FocalTherics Stock Up 0.5%

Shares of FocalTherics stock opened at $4.41 on Thursday. The firm has a 50 day moving average of $5.32. The stock has a market cap of $165.51 million, a price-to-earnings ratio of -4.28 and a beta of -0.04. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79. FocalTherics has a 52 week low of $1.50 and a 52 week high of $6.40.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter.

Institutional Investors Weigh In On FocalTherics

Several hedge funds have recently added to or reduced their stakes in FOCL. SmartHarvest Portfolios LLC acquired a new position in FocalTherics in the 1st quarter worth about $38,000. Lido Advisors LLC purchased a new position in FocalTherics during the first quarter worth approximately $40,000. Kovack Advisors Inc. acquired a new stake in FocalTherics in the fourth quarter valued at approximately $53,000. Rock Springs Capital Management LP grew its holdings in FocalTherics by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after purchasing an additional 16,500 shares during the period. Finally, Leonteq Securities AG purchased a new stake in shares of FocalTherics in the fourth quarter valued at approximately $313,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at FocalTherics

In other FocalTherics news, Director David R. Horn purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $47,500. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Joshua Levine purchased 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at $213,750. The trade was a 28.57% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 116,000 shares of company stock valued at $551,000 over the last quarter. Company insiders own 10.10% of the company’s stock.

Key Headlines Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $10 price target, implying substantial upside from the reported $4.41 reference price. The firm also raised its FY2027 EPS estimate to a loss of $0.47 from $0.54 and improved estimates for the third quarter of 2026 and the first three quarters of 2027. HC Wainwright Reiterates Buy Rating for FocalTherics
• Positive Sentiment: The analyst projects continued earnings improvement over the longer term, forecasting smaller losses in FY2028 and profitability of $0.05 per share in FY2029 and $0.25 per share in FY2030. These estimates support the longer-term growth case for FOCL. HC Wainwright FocalTherics Earnings Estimates
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the figures show no meaningful short position, they offer little evidence of either short-covering support or bearish pressure.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $0.82 from $0.78 and expects a $0.20-per-share loss in the fourth quarter. FocalTherics is already loss-making, with a recent quarterly EPS miss and negative net margin, so near-term profitability and execution remain key risks.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.